Barinthus Biotherapeutics (NASDAQ:BRNS) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reissued their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS) in a research note released on Thursday, Benzinga reports. HC Wainwright currently has a $5.00 price target on the stock.

A number of other analysts also recently issued reports on the company. William Blair reaffirmed an outperform rating on shares of Barinthus Biotherapeutics in a report on Thursday, June 13th. Alliance Global Partners decreased their target price on Barinthus Biotherapeutics from $11.00 to $9.50 and set a buy rating for the company in a research note on Tuesday, August 13th. Finally, Barclays lowered their price target on Barinthus Biotherapeutics from $7.00 to $3.00 and set an overweight rating for the company in a report on Thursday, June 13th.

Barinthus Biotherapeutics Stock Performance

Shares of Barinthus Biotherapeutics stock opened at $1.18 on Thursday. The business has a 50-day simple moving average of $1.31 and a 200-day simple moving average of $1.86. The company has a market cap of $46.52 million, a PE ratio of -0.64 and a beta of -0.53. Barinthus Biotherapeutics has a one year low of $1.11 and a one year high of $5.10.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.01). On average, sell-side analysts predict that Barinthus Biotherapeutics will post -1.71 earnings per share for the current fiscal year.

Institutional Trading of Barinthus Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. M&G Plc acquired a new stake in shares of Barinthus Biotherapeutics in the 2nd quarter valued at about $7,276,000. Alphabet Inc. acquired a new stake in shares of Barinthus Biotherapeutics in the second quarter valued at approximately $2,119,000. DC Funds LP purchased a new position in shares of Barinthus Biotherapeutics during the first quarter worth approximately $1,528,000. BlueCrest Capital Management Ltd acquired a new position in shares of Barinthus Biotherapeutics in the 1st quarter valued at $1,292,000. Finally, Ipswich Investment Management Co. Inc. purchased a new stake in Barinthus Biotherapeutics in the 2nd quarter valued at $32,000. Institutional investors and hedge funds own 25.20% of the company’s stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.